Somatic or acquired mutations are postzygotic genetic variations that can occur within any
tissue. These mutations accumulate during aging and have classically been linked to …

Chromosomal instability (CIN) is a hallmark of cancer and a driver of metastatic
dissemination, therapeutic resistance, and immune evasion. CIN is present in 60–80% of …

Recent studies on pediatric acute myeloid leukemia (pAML) have revealed pediatric-specific
driver alterations, many of which are underrepresented in the current classification schemas …

Venetoclax+ hypomethylating agent (Ven‐HMA) is currently the standard frontline therapy
for older/unfit patients with newly diagnosed acute myeloid leukemia (ND‐AML). Our …

We describe 1000 patients with essential thrombocythemia seen at the Center Research
and Innovation of Myeloproliferative Neoplasms (CRIMM), Florence, Italy, between 1980 …

Background A close association between hereditary alpha‐tryptasemia (HAT) and mast cell
(MC) disorders has been previously reported. However, the relationship between HAT and …

We describe 1000 patients with essential thrombocythemia seen at the Mayo Clinic between
1967 and 2023: median age 58 years (18–90), females 63%, JAK2/CALR/MPL-mutated …

The primary objective of treatment in myelofibrosis (MF) is prolongation of life, which is
currently accomplished only by allogeneic hematopoietic stem cell transplantation (AHSCT) …

Essential thrombocythemia is a Janus kinase 2 (JAK2) mutation-prevalent myeloproliferative
neoplasm characterized by clonal thrombocytosis; clinical course is often indolent but might …

Molecularly defined secondary acute myeloid leukemia is associated with a prior myeloid
neoplasm and confers a worse prognosis. We compared outcomes of molecularly defined …